CBS001
/ Centessa
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
September 22, 2023
Study of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=56 | Terminated | Sponsor: Capella Bioscience Ltd | N=88 ➔ 56 | Trial completion date: Dec 2023 ➔ Aug 2023 | Suspended ➔ Terminated | Trial primary completion date: Dec 2023 ➔ Aug 2023; Portfolio reprioritization
Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Inflammation
January 17, 2023
Study of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=88 | Suspended | Sponsor: Capella Bioscience Ltd | Recruiting ➔ Suspended
Trial suspension • Inflammation
April 21, 2022
Study of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=88 | Recruiting | Sponsor: Capella Bioscience Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Inflammation
1 to 3
Of
3
Go to page
1